Italy
· Delayed Price · Currency is EUR BridgeBio Pharma Statistics
Total Valuation
BIT:1BBIO has a market cap or net worth of EUR 6.46 billion. The enterprise value is 7.63 billion.
| Market Cap | 6.46B |
| Enterprise Value | 7.63B |
Important Dates
The next estimated earnings date is Friday, August 1, 2025.
| Earnings Date | Aug 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +11.59% |
| Shares Change (QoQ) | +0.37% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 139.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 54.79 |
| PB Ratio | -4.26 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -12.35 |
| EV / Sales | 67.90 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -16.47 |
Financial Position
The company has a current ratio of 4.57
| Current Ratio | 4.57 |
| Quick Ratio | 4.31 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.71 |
| Interest Coverage | -5.67 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -48.27% |
| Return on Invested Capital (ROIC) | -91.66% |
| Return on Capital Employed (ROCE) | -91.62% |
| Revenue Per Employee | 161,929 |
| Profits Per Employee | -848,907 |
| Employee Count | 730 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 40 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.16 |
Income Statement
In the last 12 months, BIT:1BBIO had revenue of EUR 117.88 million and -618.00 million in losses. Loss per share was -3.27.
| Revenue | 117.88M |
| Gross Profit | 112.41M |
| Operating Income | -618.42M |
| Pretax Income | -625.10M |
| Net Income | -618.00M |
| EBITDA | -613.08M |
| EBIT | -618.42M |
| Loss Per Share | -3.27 |
Balance Sheet
The company has 500.16 million in cash and 1.72 billion in debt, giving a net cash position of -1.22 billion.
| Cash & Cash Equivalents | 500.16M |
| Total Debt | 1.72B |
| Net Cash | -1.22B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -1.52B |
| Book Value Per Share | -8.03 |
| Working Capital | 502.45M |
Cash Flow
In the last 12 months, operating cash flow was -462.99 million and capital expenditures -220,198, giving a free cash flow of -463.21 million.
| Operating Cash Flow | -462.99M |
| Capital Expenditures | -220,198 |
| Free Cash Flow | -463.21M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 95.35% |
| Operating Margin | -524.60% |
| Pretax Margin | -530.27% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BIT:1BBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.59% |
| Shareholder Yield | -11.59% |
| Earnings Yield | -9.57% |
| FCF Yield | -7.17% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BIT:1BBIO has an Altman Z-Score of -5.54. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.54 |
| Piotroski F-Score | n/a |